The antimycotic imidazoles clotrimazole and miconazole inhibit susceptible fungi by two mechanisms (I. J. Sud and D. S. Feingold, J. Invest. Dermatol., in press). At low concentrations they block demethylation of lanosterol to the major fungal sterol ergosterol (6, 9, 12, 14) . Fungistatic concentrations of clotrimazole and miconazole increase lanosterol/ergosterol ratios in Saccharomyces cerevisiae (Sud and Feingold, in press ). Accumulation of the bulky lanosterol molecule is likely responsible for the growth inhibition (10) . Under strictly anaerobic conditions, S. cerevisiae cannot synthesize sterols and will not grow unless a sterol and an unsaturated free fatty acid are added to the medium (1) . Miconazole and clotrimazole have a sharply elevated minimal inhibitory concentration (MIC) for the yeast growing anaerobically under these conditions. At a concentration of the imidazoles 30 to 60 times the usual aerobic MIC, however, these imidazoles are fungicidal both aerobically and anaerobically (Sud and Feingold, in press). The fungicidal action is distinct from the fungistatic one described above. At higher concentrations the imidazoles are rapidly fungicidal as evidenced by viable counts and the entry of methylene blue into the cells within minutes of drug addition (Sud and Feingold, in press ). It is likely that the locus of the immediate lethal effect of these imidazoles is on fungal membranes, and this is further reflected in the liposome disruptive ability of the imidazoles (13, 17) , especially prominent when the liposome model membranes are rich in free unsaturated fatty acids.
We refer to the low-concentration, fungistatic effect on sterol synthesis as the sterol synthesis inhibition and to the rapid fungicidal action as direct membrane damage (DMD). When we examined the action of the new imidazole ketoconazole in the systems described above a remarkable difference was seen. Against S. cerevisiae ketoconazole has a potent sterol synthesis inhibition action, but showed little or no DMD effect. This fact may have important clinical ramifications as will be discussed.
MATERIALS AND METHODS
Organism and growth conditions. S. cerevisiae ATCC 287 was grown aerobically and anaerobically as we have described in detail (Sud and Feingold, in press ). The broth (pH 7.0) cultures were incubated at 34WC. For anaerobic cultures, the broth was supplemented with ergosterol (20 jig/ml) and Tween 80 (10 ,Ag/mI). All the imidazoles were used as the free base. The inoculum size was about 103 organisms per ml. The MIC was the lowest concentration of the antimicrobial agent causing inhibition as judged by the absence of turbidity. Stock solutions of the imidazoles were made in dimethyl sulfoxide; the concentration of this solvent when added to broth was always 1% or less.
Lanosterol/ergosterol ratios. For studies of the sterol composition, flasks containing broth with various concentrations of drugs were inoculated at 104 cells per ml and then incubated aerobically for 24 h.
Cultures showing turbidity were processed further for isolation and determination of sterol composition as described elsewhere (Sud and Feingold, in press).
Briefly, the cells were treated with 5% trichloroacetic acid, washed, and then saponified with methanolic KOH. The petroleum ether extracts were then subjected to gas-liquid chromatography to determine ergosterol and lanosterol content of cells.
Effect of imidazoles on viability. Broths containing various concentrations of the imidazoles were inoculated with a log-phase culture to give a starting population of approximately 103 organisms per ml. The cultures were shaken aerobically at 34°C, and samples taken over a 9-h time span were plated on agar plates after appropriate dilutions for determination of viable counts.
Methylene blue uptake. Details of the method used to determine methylene blue uptake have been described in detail (Sud and Feingold, in press ). Briefly, the drug-treated cells were exposed to aqueous methylene blue, and the percentage of uniformly stained cells was determined microscopically. Control experiments showed that cells killed either by boiling for 5 min or by exposure to formaldehyde were 100% stained, whereas fewer than 3% of cells from growing cultures were stained.
Liposome preparation and testing. Liposomes were prepared and their imidazole susceptibility was tested as previously described by us (7) . The liposomes contained phosphatidylcholine, dicetyl phosphate, and oleic acid in molar ratios of 60:10:30. Glucose was used as a marker molecule. Liposomes were exposed to various drug concentrations for 1 h at room temperature. Glucose released was measured enzymatically by a modification (13) of the method described by Kinsky et al. (8) . Table 1 shows the MICs for S. cerevisiae for the three tested imidazoles aerobically and anaerobically. Ketoconazole had an MIC similar to that of clotrimazole under aerobic conditions; miconazole was more potent in this system. However, the anaerobic MIC value was very different for ketoconazole than for the others (Table 1 ). There was growth of S. cerevisiae at the highest ketoconazole concentration employed, 200 ,g/ml (3.8 x 10' M). This finding suggests that ketoconazole has a very weak or no DMD action on S. cerevisiae since under these anaerobic conditions DMD is the only operative antifungal mechanism (Sud and Feingold, in press).
RESULTS
As with the other imidazoles, ketoconazole at subinhibitory levels also caused an increase in the lanosterol/ergosterol ratio. In Table 2 results with ketoconazole are compared with those we have already reported for clotrimazole and miconazole (Sud and Feingold, in press). At 3 x 10-7 M ketoconazole the ratio was 0.92, whereas control cells had a ratio of 0.05. Increase of the ratio was first detected at 3 x 10-8 M ketoconazole. It seems clear that ketoconazole like clotrimazole and miconazole blocks demethylation of lanosterol to ergosterol at low concentrations; very likely this is an important mechanism in vivo as well as in vitro (14) . Table 3 shows the comparative effects of ketoconazole and miconazole on methylene blue uptake by S. cerevisiae as a function of imidazole concentration. There was very little methylene blue staining caused by ketoconazole even at a 10-' M concentration. Methylene blue staining induced by miconazole began at 10-' M and approached 100% by 10-4 M. This correlates quite well with the lethal effect of miconazole. Results with clotrimazole were similar to those with miconazole (Sud and Feingold, in press). Figure 1 shows the striking differences in the effect of miconazole, clotrimazole, and ketoconazole on viable counts of S. cerevisiae as a function of drug concentration and time. Miconazole and clotrimazole showed prompt fungicidal action at 10-4 M and above under these conditions.
As shown in the figure ketoconazole caused no killing even at 10-' M. Growth inhibition with increasing ketoconazole concentrations began at 3.3 x 10-7 M and was prompt and complete at 10-4 M. However, under no conditions we tested was it fungicidal. Figure 2 compares the three imidazoles in their effect on liposomes. The liposomes used consisted of phosphatidyl choline-dicetyl phosphate-oleic acid in molar ratios of 60:10:30. Such liposomes were shown previously to be very susceptible to miconazole and clotrimazole (13) . In the experiments shown in the figure, similar results for marker release as a function of the imidazole concentration were seen with miconazole and clotrimazole. Ketoconazole caused much less marker release in the system at all concentrations tested up to 100,ug/ml. DISCUSSION Miconazole and clotrimazole have at least two distinct antifungal mechanisms, sterol synthesis inhibition and DMD (Sud and Feingold, in press ). Ketoconazole differs fundamentally from clotrimazole and miconazole in that it has very weak or no DMD action when compared to the others. This is reflected in a lack of fungicidal action of ketoconazole (Fig. 1) , an absence of an effect of ketoconazole anaerobically (Table 1) , and inability ofketoconazole to foster methylene blue entry into S. cerevisiae (Table 3) .
Ketoconazole is being hailed as "a major innovation for treatment of fungal disease" (3) . Unlike other imidazoles it gives substantial blood levels after oral administration, and toxicity observed so far is minimal (2, 3, 5, 11) . It may be that the DMD effect of the imidazoles in mammalian cells is responsible for imidazole toxicity in humans and, hence, the apparent miniimal toxicity of ketoconazole versus miconazole in the early clinical studies.
The dual mechanism of action of clotrimazole and miconazole might explain the extremely rare development of clinically important fungal resistance to clotrimazole and miconazole. Our experience also is that it is extremely difficult to isolate imidazole resistant strains (unpublished observation). Since ketoconazole lacks DMD action the emergence of resistant strains in clinical settings may present a greater problem with this imidazole than with clotrimazole or miconazole.
The absence of a rapid fungicidal action of ketoconazole may also present a problem, especially during long-term treatment of fungal in- 
